Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 18/20 | 0.63 |
| ▸ | CNR1 | P21554 | 6/20 | 0.63 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14995856 | 0.83 | PFKFB3 (0.46) | CNR2CNR1PFKFB3PPARG | |
| SCHEMBL2372639 | 0.79 | CNR2 (0.48) | CNR2CNR1PFKFB3 | |
| SCHEMBL2371777 | 0.78 | PFKFB3 (0.46) | CNR2CNR1PFKFB3PPARG | |
| SCHEMBL3036367 | 0.78 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3036786 | 0.77 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3042516 | 0.77 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3018967 | 0.77 | HTT (0.49) | CNR2CNR1PFKFB3 | |
| SCHEMBL3018096 | 0.76 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL3038867 | 0.75 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL2371775 | 0.75 | PFKFB3 (0.46) | CNR2CNR1PFKFB3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2139852-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | Pharmos Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008075353-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | SULT2A1, STS, SULT1A1 | CNR2 41/4885CNR1 207/4885PFKFB3 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.